FI964332A - Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen - Google Patents

Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen Download PDF

Info

Publication number
FI964332A
FI964332A FI964332A FI964332A FI964332A FI 964332 A FI964332 A FI 964332A FI 964332 A FI964332 A FI 964332A FI 964332 A FI964332 A FI 964332A FI 964332 A FI964332 A FI 964332A
Authority
FI
Finland
Prior art keywords
prosthesis
acid derivatives
pct
migration
loosening
Prior art date
Application number
FI964332A
Other languages
English (en)
Swedish (sv)
Other versions
FI964332A0 (fi
FI118590B (fi
Inventor
Allen E Goodship
John Kenwright
Jonathan Green
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of FI964332A0 publication Critical patent/FI964332A0/fi
Publication of FI964332A publication Critical patent/FI964332A/fi
Application granted granted Critical
Publication of FI118590B publication Critical patent/FI118590B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Dental Preparations (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI964332A 1994-05-04 1996-10-28 1-hydroksi -2- (imidatsol -1-yyli) etaani -1,1 -difosfonihapon käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen FI118590B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9408775A GB9408775D0 (en) 1994-05-04 1994-05-04 Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
GB9408775 1994-05-04
PCT/IB1995/000288 WO1995030421A1 (en) 1994-05-04 1995-04-24 Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
IB9500288 1995-04-24

Publications (3)

Publication Number Publication Date
FI964332A0 FI964332A0 (fi) 1996-10-28
FI964332A true FI964332A (fi) 1996-10-28
FI118590B FI118590B (fi) 2008-01-15

Family

ID=10754497

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964332A FI118590B (fi) 1994-05-04 1996-10-28 1-hydroksi -2- (imidatsol -1-yyli) etaani -1,1 -difosfonihapon käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen

Country Status (18)

Country Link
US (1) US5965547A (fi)
EP (1) EP0758241B1 (fi)
JP (1) JPH09512816A (fi)
AT (1) ATE218350T1 (fi)
AU (1) AU693541B2 (fi)
DE (1) DE69526937T2 (fi)
DK (1) DK0758241T3 (fi)
ES (1) ES2177642T3 (fi)
FI (1) FI118590B (fi)
GB (1) GB9408775D0 (fi)
HU (1) HUT74984A (fi)
IL (1) IL113566A (fi)
NO (1) NO310057B1 (fi)
NZ (1) NZ283430A (fi)
PT (1) PT758241E (fi)
TW (1) TW458779B (fi)
WO (1) WO1995030421A1 (fi)
ZA (1) ZA953537B (fi)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US6117856A (en) * 1996-02-14 2000-09-12 Binderman; Itzhak Topical bisphosphonates for prevention of bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
GB2336311A (en) * 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
US6137012A (en) 1998-10-13 2000-10-24 E. I. Du Pont De Nemours And Company Phosphole and diphosphole ligands for catalysis
ATE303153T1 (de) * 1998-12-04 2005-09-15 Roche Diagnostics Gmbh Ibandroinsäure zur förderung der osseointegration der endoprothesen
CA2360319A1 (en) * 1999-02-09 2000-08-17 Memorial Sloan-Kettering Cancer Center Anti-resorptive bone cements and allogeneic, autografic, and xenografic bone grafts
CA2346014A1 (en) * 1999-08-02 2001-02-08 Toray Industries, Inc. Implant attachement stabilizer
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
SI1591122T1 (sl) 2000-06-20 2013-02-28 Novartis Ag Postopek za aplikacijo bisfosfonatov
HU228400B1 (en) * 2000-06-20 2013-03-28 Novartis Ag The use of bisphosphonates for treatment of osteoporosis
WO2002004038A1 (en) * 2000-07-12 2002-01-17 Hopital Orthopedique De La Suisse Romande Active biocoating for bone implant
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
ES2532393T3 (es) * 2002-05-10 2015-03-26 F. Hoffmann-La Roche Ag Acidos bisfosfónicos para tratamiento y prevención de osteoporosis
ATE532523T1 (de) * 2002-09-16 2011-11-15 Novartis Pharma Gmbh Zoledronsäure zur prävention oder verminderung von sekundärfrakturen nach hüftfraktur
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
EP2088996A1 (en) * 2006-11-17 2009-08-19 Besins Healthcare Liquid pharmaceutical compositions comprising a bisphosphonate compound
EP1958649A1 (en) * 2007-02-14 2008-08-20 Graftys Injectable calcium-phosphate cement releasing a bone resorption inhibitor
EP2136814A4 (en) * 2007-03-21 2012-05-30 Univ Duke MEDICAL KITS AND FORMULATIONS FOR PREVENTING, TREATING OR REDUCING SECONDARY FRACTURES FROM A PREVIOUS FRACTURE
US20100317859A1 (en) * 2007-05-16 2010-12-16 Actavis Group Ptc Ehf Process for the Preparation of Risedronate Sodium
ES2537216T3 (es) 2009-09-01 2015-06-03 Duke University Composiciones de bisfosfonato y métodos para tratar la insuficiencia cardíaca
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
WO2013074587A1 (en) 2011-11-16 2013-05-23 Duke University Bishophonate compositions and methods for treating and/or reducing cardiac dysfunction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE10199052I1 (de) * 1986-11-21 2002-01-10 Novartis Ag Neue substituierte Alkandiphosphonsaeuren
JPH05163150A (ja) * 1991-05-13 1993-06-29 E R Squibb & Sons Inc アテローム性動脈硬化症の抑制・治療剤
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices

Also Published As

Publication number Publication date
US5965547A (en) 1999-10-12
EP0758241A1 (en) 1997-02-19
ES2177642T3 (es) 2002-12-16
NO964486L (no) 1996-10-22
NZ283430A (en) 2000-06-23
HU9603042D0 (en) 1997-01-28
ATE218350T1 (de) 2002-06-15
DE69526937T2 (de) 2003-01-02
TW458779B (en) 2001-10-11
JPH09512816A (ja) 1997-12-22
AU693541B2 (en) 1998-07-02
ZA953537B (en) 1995-11-06
NO310057B1 (no) 2001-05-14
EP0758241B1 (en) 2002-06-05
FI964332A0 (fi) 1996-10-28
WO1995030421A1 (en) 1995-11-16
IL113566A (en) 2002-05-23
DK0758241T3 (da) 2002-09-23
AU2146695A (en) 1995-11-29
HUT74984A (en) 1997-03-28
IL113566A0 (en) 1995-08-31
GB9408775D0 (en) 1994-06-22
DE69526937D1 (de) 2002-07-11
PT758241E (pt) 2002-10-31
FI118590B (fi) 2008-01-15
NO964486D0 (no) 1996-10-22

Similar Documents

Publication Publication Date Title
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
BG101118A (en) Therapeutical compounds
DE69400435D1 (de) Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson-syndromen
ATE226436T1 (de) Neue verwendung von dexmedetomidin
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
PT888327E (pt) Derivados de benzopirano que possuem uma accao antagonistica dos leucotrienos
FI972434A (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
IT1282736B1 (it) Uso di derivati del p-amminofenolo per preparare composizioni farmaceutiche utili nel trattamento di malattie neurodegenerative
BG105275A (en) Tan-1057 derivatives
EE9700366A (et) Angiotensiini II tüüp 1 retseptori antagonistide kasutamine düspeptiliste sümptomite profülaktikas ja/või ravis kasutatava ravimi valmistamiseks ja angiotensiini II tüüp 1 retseptori antagoniste sisaldavad ravimpreparaadid
GR3034142T3 (en) Composition for the treatment or prevention of herpes
MX9605327A (es) Uso de ciertos derivados de acido metanbisfosfonico para prevenir el aflojamiento de las protesis y la emigracion de las protesis.
ZA9427B (en) Use of riluzole for promoting restoration following radiation
CA2183764A1 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

FG Patent granted

Ref document number: 118590

Country of ref document: FI